Search PubMed⌕ Search

PubMed · 10625985

Immune dysfunction in trauma.

Abstract

This article documents that all immunomodulation strategies for patients sustaining traumatic injury are still under intense investigation. Although we can speculate that combination strategies may be more beneficial than single-agent immunomodulation approaches, comprehensive clinical studies are required to determine efficacious immune therapy for trauma patients. The only strategy available to clinicians caring for trauma patients is immunonutrition, and this should be strongly considered as a rational approach to improve immune function and reduce septic complications in critically ill or injured patients.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L M Napolitano, E Faist, M W Wichmann, R Coimbra. 1999. Immune dysfunction in trauma.. https://doi.org/10.1016/s0039-6109(05)70084-0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers.

Dendritic cells (DCs) are potent antigen-presenting cells and have shown promise to function as "natural" vaccine adjuvants. Currently, most cancer vaccine trials using DCs generate autologous DCs ex vivo for each patient. Systemic treatment with Flt3 ligand (FL) results in a marked increase of DCs in tissues such as spleen and lymph nodes in mice and in the peripheral blood and skin of humans. In light of these observations, we questioned whether FL could be used systemically as a vaccine adjuvant to stimulate DC mobilization in vivo, circumventing the need to generate DCs ex vivo. Ten patients with HER-2/neu-overexpressing cancer were enrolled in a phase 1 study to receive a HER-2/neu peptide-based vaccine targeting the intracellular domain of the HER-2/neu protein. All patients received 20 microg/kg FL per day subcutaneously for 14 days. Five patients received the HER-2/neu peptide-based vaccine alone on day 7 of the 14-day cycle, and 5 patients received the vaccine admixed with 150 microg granulocyte macrophage-colony-stimulating factor (GM-CSF) on day 7 of the FL cycle. T-cell proliferative responses to HER-2/neu peptides and intracellular domain protein suggest that vaccine regimens including FL as an adjuvant were not effective in eliciting a significant HER-2/neu protein-specific T-cell proliferative response. However, including FL as a vaccine adjuvant was effective in boosting the precursor frequency of interferon-gamma-secreting HER-2/neu-specific T cells. The small sample size of each group, however, did not allow a statistically significant comparison of immune responses between the FL alone and FL with GM-CSF arms. Finally, vaccine regimens including FL as a vaccine adjuvant were associated with the development of apparent autoimmune phenomena in some patients.

Adjuvants, Immunologic↗

Enhanced adjuvantic property of polymerized liposome as compared to a phospholipid liposome.

Liposome, although intensively researched as vaccine or drug delivery vehicle, has been of limited use due to the low and unpredictable long-term stability. In order to overcome such problems, polymerized liposome (PL) that could initiate polymerization under very mild reaction condition was examined and compared to a conventional liposome. The polymerizable lipid, 1,2-bis[12-(lipoyloxy)dodecanoyl]-sn-glycero-3-phosphorylcholine (DLL), was synthesized according to the literature, and 1,2-distearoyl-sn-glycero-3-phosphorylcholine (DSPC) was used as the conventional lipid counterpart. Polymerization of liposome was as easy and convenient as just shaking in pH 7.4 buffer. The protein encapsulation efficiency of DLL was higher than that of DSPC, and its protein release rate was lower. Immunoglobulin G (IgG) activity examined after intraperitoneal injection of antigen encapsulated by either DLL or DSPC showed that ca. 2 times as much antibody was formed by DLL-encapsulated lysozyme compared with DSPC-encapsulated form. The reasons for the superior adjuvantic properties of DLL and its future application as a drug delivery system are briefly discussed.

Adjuvants, Immunologic↗